Literature DB >> 12777599

Anaphylaxis and emergency treatment.

Hugh A Sampson1.   

Abstract

Food anaphylaxis is now the leading known cause of anaphylactic reactions treated in emergency departments in the United States. It is estimated that there are 30 000 anaphylactic reactions to foods treated in emergency departments and 150 to 200 deaths each year. Peanuts, tree nuts, fish, and shellfish account for most severe food anaphylactic reactions. Although clearly a form of immunoglobulin E-mediated hypersensitivity, the mechanistic details responsible for symptoms of food-induced anaphylaxis are not completely understood, and in some cases, symptoms are not seen unless the patient exercises within a few hours of the ingestion. At the present time, the mainstays of therapy include educating patients and their caregivers to strictly avoid food allergens, to recognize early symptoms of anaphylaxis, and to self-administer injectable epinephrine. However, clinical trials are now under way for the treatment of patients with peanut anaphylaxis using recombinant humanized anti-immunoglobulin E antibody therapy, and novel immunomodulatory therapies are being tested in animal models of peanut-induced anaphylaxis.

Entities:  

Mesh:

Year:  2003        PMID: 12777599

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  80 in total

1.  [Not Available].

Authors:  A Cheng
Journal:  Paediatr Child Health       Date:  2011-01       Impact factor: 2.253

2.  Anaphylaxis as an adverse event following immunisation.

Authors:  Michel Erlewyn-Lajeunesse; Jan Bonhoeffer; Jens U Ruggeberg; Paul T Heath
Journal:  J Clin Pathol       Date:  2007-05-04       Impact factor: 3.411

Review 3.  A comprehensive review of legume allergy.

Authors:  Alok Kumar Verma; Sandeep Kumar; Mukul Das; Premendra D Dwivedi
Journal:  Clin Rev Allergy Immunol       Date:  2013-08       Impact factor: 8.667

Review 4.  Update on oral immunotherapy for egg allergy.

Authors:  François Graham; Natacha Tardio; Louis Paradis; Anne Des Roches; Philippe Bégin
Journal:  Hum Vaccin Immunother       Date:  2017-10-03       Impact factor: 3.452

5.  Rate of recurrent anaphylaxis and associated risk factors among Olmsted County, Minnesota, residents: A population-based study.

Authors:  Sangil Lee; Curtis Bashore; Christine M Lohse; M Fernanda Bellolio; Alanna Chamberlain; Kumi Yuki; Erik P Hess; Ronna L Campbell
Journal:  Ann Allergy Asthma Immunol       Date:  2016-12       Impact factor: 6.347

6.  Emergency treatment of anaphylaxis in infants and children.

Authors:  A Cheng
Journal:  Paediatr Child Health       Date:  2011-01       Impact factor: 2.253

7.  Determination of the enantiomeric purity of epinephrine by HPLC with circular dichroism detection.

Authors:  Douglas Kirkpatrick; Jingyue Yang; Michael Trehy
Journal:  J Liq Chromatogr Relat Technol       Date:  2017-05-31       Impact factor: 1.312

8.  Persistent, refractory, and biphasic anaphylaxis: A multidisciplinary Delphi study.

Authors:  Timothy E Dribin; Hugh A Sampson; Carlos A Camargo; David C Brousseau; Jonathan M Spergel; Mark I Neuman; Marcus Shaker; Ronna L Campbell; Kenneth A Michelson; Susan A Rudders; Amal H Assa'ad; Kimberly A Risma; Mariana Castells; Lynda C Schneider; Julie Wang; Juhee Lee; Rakesh D Mistry; David Vyles; Lisa M Vaughn; Daniel J Schumacher; John K Witry; Shiv Viswanathan; Erica M Page; David Schnadower
Journal:  J Allergy Clin Immunol       Date:  2020-08-24       Impact factor: 10.793

9.  The Key Events Dose-Response Framework: a foundation for examining variability in elicitation thresholds for food allergens.

Authors:  Steve L Taylor; Steven M Gendel; Geert F Houben; Elizabeth Julien
Journal:  Crit Rev Food Sci Nutr       Date:  2009-09       Impact factor: 11.176

10.  Oral desensitization to milk: how to choose the starting dose!

Authors:  Francesca Mori; Neri Pucci; Maria Elisabetta Rossi; Maurizio de Martino; Chiara Azzari; Elio Novembre
Journal:  Pediatr Allergy Immunol       Date:  2009-07-13       Impact factor: 6.377

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.